|Last Update: 05/23/13 - 2:00 PM EDT|
|YTD Performance: -1.94%|
|Previous Close: $13.52|
|52 Week Range: $9.86 - $31.21|
|Oustanding Shares: 100,665,029|
|Market Cap: 1,324,751,782|
|Qtr (06/13)||Qtr (09/13)||FY (12/13)||FY (12/14)|
|Number of Analysts||6||5||7||6|
|Growth Rate (Year over Year)||-104.17%||50.50%||-34.21%||50.15%|
VVUS was downgraded from Buy to Neutral, Lazard Capital Markets said. The window of opportunity is closing for Qsymia in the obesity market.
Shares of VVUS now seen reaching $30, according to JMP Securities. Estimates also cut, given lower expected Qsymia sales. Outperform rating.
VVUS was added to the US 1 list, according to Bank of America/Merrill Lynch said. $30 price target. Retail distribution approval should boost Qsymia sales.
Shares of VVUS now seen reaching $27, according to Lazard. Estimates also cut, given a sluggish expected launch for Qysmia. Buy rating.
Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.
Jim Cramer says we should throw out the ADP report and the BLS should out source the work to TIBCO.
Shares of VVUS now seen reaching $29, according to Credit Suisse. EU may not approve Qsymia. Outperform rating.
Adam Feuerstein, Sr. Columnist for TheStreet, says obesity drugs are the next big thing to watch in biotech.
VVUS was upgraded to Buy, Lazard said. New analyst has a $36 price target. Obesity drug should drive growth over the next several quarters.
Adam Feuerstein, Sr. Columnist for TheStreet, says post FDA approval trading is the next big thing to watch in biotech.